Last update Dec. 23, 2024

Siponimod, Siponimod Fumarate

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is an immunomodulator with actions similar to those of fingolimod, but has a shorter half-life. It is used in the treatment of patients with relapsing forms of multiple sclerosis. Oral administration once daily.

At the date of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (large volume of distribution, moderately high molecular weight, -more so in the case of fumarate-, and very high percentage of binding to plasma proteins) make passage into breast milk in significant quantities very unlikely.

Since its side effects can be frequent and severe, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity. 

If administered during breastfeeding, it is advisable to monitor the appearance of symptoms (vomiting, diarrhea, poor feeding, irritability...) in the infant. (Mother 2024)


See below the information of this related product:

  • Maternal Multiple Sclerosis (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Siponimod, Siponimod Fumarate in other languages or writings:

Group

Siponimod, Siponimod Fumarate belongs to this group or family:

Tradenames

Main tradenames from several countries containing Siponimod, Siponimod Fumarate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 84 %
Molecular weight 517 ; 1.149 daltons
Protein Binding 99.9 %
VD 1.77 l/Kg
pKa 3.33 -
Tmax 4 (2 - 12) hours
30 hours

References

  1. EMA. Siponimod. Ficha técnica. 2024 Full text (in our servers)
  2. Novartis. Siponimod. Drug Summary. 2020 Full text (in our servers)
  3. Mother To Baby. Siponimod (Mayzent®).. 1994 - 2024 Apr. Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994-. Abstract Full text (link to original source)

Total visits

110

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Amamanta of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM